The European Academy of Neurology (EAN) 2026 congress was a reminder that neurology sits at a pivotal moment. Scientific understanding of neurological conditions is advancing quickly, but clinical practice, endpoint design, and commercial strategy are working to keep pace. From debates around Alzheimer’s biomarker interpretation to the crowding of the myasthenia gravis and migraine markets, EAN 2026 surfaced the tensions that will define the next chapter of neurological drug development and commercialization.

Across the congress, four themes stood out for their strategic relevance and cross-condition resonance. Together, they point toward a clear conclusion: precision medicine in neurology is no longer aspirational — it is an emerging clinical and commercial necessity. Check out all the insights.

Read the full list of insights

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Sign me up to receive regular insights from Lumanity
By selecting this box, I consent to receive Lumanity marketing communications by email.